Renaissance Technologies LLC Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Renaissance Technologies LLC raised its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 157.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 243,740 shares of the company's stock after purchasing an additional 148,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.24% of Day One Biopharmaceuticals worth $3,088,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals in the 4th quarter valued at $866,000. Hennion & Walsh Asset Management Inc. raised its position in Day One Biopharmaceuticals by 90.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company's stock valued at $1,535,000 after purchasing an additional 57,601 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Day One Biopharmaceuticals by 10.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company's stock valued at $19,961,000 after buying an additional 136,458 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Day One Biopharmaceuticals by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company's stock valued at $6,785,000 after buying an additional 28,053 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Day One Biopharmaceuticals by 2.3% in the 3rd quarter. Franklin Resources Inc. now owns 3,869,632 shares of the company's stock valued at $55,336,000 after buying an additional 87,262 shares during the period. Institutional investors own 87.95% of the company's stock.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares of the company's stock, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock valued at $251,925 over the last ninety days. 6.20% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Stock Down 0.9 %

Shares of NASDAQ:DAWN traded down $0.07 during mid-day trading on Tuesday, reaching $7.67. 131,455 shares of the stock were exchanged, compared to its average volume of 1,059,044. The company has a market cap of $777.69 million, a P/E ratio of -7.45 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a one year low of $6.41 and a one year high of $18.07. The stock's 50 day simple moving average is $8.27 and its 200-day simple moving average is $11.53.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. Analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DAWN shares. The Goldman Sachs Group lowered their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Wedbush reaffirmed an "outperform" rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals has an average rating of "Buy" and a consensus target price of $32.29.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.